Goldman Sachs Group set a €77.00 ($89.53) price target on Bayer (FRA:BAYN) in a research note published on Monday morning, Borsen Zeitung reports. The brokerage currently has a buy rating on the healthcare company’s stock.

BAYN has been the topic of several other research reports. Barclays set a €85.00 ($98.84) price target on Bayer and gave the company a buy rating in a research note on Tuesday, July 30th. Berenberg Bank set a €67.00 ($77.91) price target on Bayer and gave the company a neutral rating in a research note on Wednesday, July 31st. Kepler Capital Markets set a €70.00 ($81.40) price target on Bayer and gave the company a neutral rating in a research note on Thursday, June 27th. Warburg Research set a €61.00 ($70.93) price target on Bayer and gave the company a neutral rating in a research note on Wednesday, August 7th. Finally, Independent Research set a €53.00 ($61.63) price target on Bayer and gave the company a sell rating in a research note on Thursday, August 1st. One analyst has rated the stock with a sell rating, eleven have given a hold rating and twelve have given a buy rating to the stock. Bayer currently has an average rating of Hold and an average target price of €80.57 ($93.68).

Bayer stock opened at €62.98 ($73.23) on Monday. The business has a fifty day simple moving average of €59.42. Bayer has a 52 week low of €91.58 ($106.49) and a 52 week high of €123.82 ($143.98).

Bayer Company Profile

Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.

See Also: What is an investor looking for in an SEC filing?

Analyst Recommendations for Bayer (FRA:BAYN)

Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.